Xtx Topco LTD Heron Therapeutics, Inc. Transaction History

Xtx Topco LTD

$710 Million
Q1 2024

A detailed history of Xtx Topco LTD transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 208,787 shares of HRTX stock, worth $730,754. This represents 0.08% of its overall portfolio holdings.

Number of Shares

208,787

Previous 104,274 100.23%

Holding current value

$730,754

Previous $177,000 226.55%

% of portfolio

0.08%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.71 - $3.06 $178,717 - $319,809	104,513 Added 100.23%	208,787 $578,000
Q4 2023 Feb 13, 2024	BUY	$0.54 - $1.82 $56,307 - $189,778	104,274 New	104,274 $177,000
Q2 2023 Aug 14, 2023	BUY	$1.11 - $2.88 $190,754 - $494,930	171,851 Added 72.83%	407,825 $473,000
Q1 2023 May 12, 2023	SELL	$1.51 - $3.25 $167,705 - $360,954	-111,063 Reduced 32.0%	235,974 $356,000
Q4 2022 Feb 14, 2023	BUY	$2.25 - $4.67 $598,306 - $1.24 Million	265,914 Added 327.79%	347,037 $867,000

Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $8,083 - $16,319	3,039 Added 3.89%	81,123 $342,000
Q2 2022 Aug 15, 2022	BUY	$2.3 - $6.29 $132,590 - $362,605	57,648 Added 282.09%	78,084 $218,000
Q1 2022 May 13, 2022	BUY	$4.63 - $9.94 $94,618 - $203,133	20,436 New	20,436 $117,000
Q4 2021 Feb 11, 2022	SELL	$8.35 - $12.6 $223,871 - $337,818	-26,811 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.13 - $15.0 $271,595 - $402,165	26,811 New	26,811 $287,000
Q2 2021 Aug 12, 2021	SELL	$13.27 - $18.48 $157,541 - $219,394	-11,872 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$14.49 - $20.72 $172,025 - $245,987	11,872 New	11,872 $192,000

Others Institutions Holding HRTX

# of Institutions

168

Shares Held

119M

Call Options Held

151K

Put Options Held

103K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $416M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account